MARI.VI Stock - Marinomed Biotech AG
Unlock GoAI Insights for MARI.VI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.75M | $9.18M | $11.28M | $11.63M | $8.12M |
| Gross Profit | $-4,267,870 | $1.14M | $2.14M | $1.42M | $-641,700 |
| Gross Margin | -89.9% | 12.4% | 19.0% | 12.2% | -7.9% |
| Operating Income | $-7,021,952 | $-5,129,200 | $-5,751,300 | $-4,144,700 | $-6,960,800 |
| Net Income | $-15,416,397 | $-6,794,800 | $-6,397,700 | $-5,891,300 | $-6,010,200 |
| Net Margin | -324.8% | -74.0% | -56.7% | -50.7% | -74.0% |
| EPS | $-8.67 | $-4.48 | $-4.27 | $-3.99 | $-4.09 |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Visit WebsiteEarnings History & Surprises
MARI.VIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 17, 2025 | — | $11.68 | — | — |
Q2 2025 | May 8, 2025 | — | — | — | — |
Q2 2025 | Apr 16, 2025 | — | — | — | — |
Q4 2024 | Nov 21, 2024 | — | — | — | — |
Q3 2024 | Aug 20, 2024 | — | $-5.65 | — | — |
Q2 2024 | May 22, 2024 | — | $-1.39 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.78 | — | — |
Q4 2023 | Nov 21, 2023 | — | $-1.38 | — | — |
Q3 2023 | Aug 17, 2023 | — | $-0.96 | — | — |
Q2 2023 | May 23, 2023 | — | $-1.37 | — | — |
Q2 2023 | Apr 19, 2023 | — | $-0.40 | — | — |
Q4 2022 | Nov 21, 2022 | — | $-1.29 | — | — |
Q3 2022 | Jul 21, 2022 | — | $-1.37 | — | — |
Q2 2022 | Apr 13, 2022 | — | $0.28 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.23 | — | — |
Q4 2021 | Nov 22, 2021 | — | $-1.30 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-1.55 | — | — |
Q2 2021 | May 26, 2021 | — | $-1.42 | — | — |
Q2 2021 | Apr 14, 2021 | — | $-0.83 | — | — |
Q4 2020 | Nov 26, 2020 | — | $-1.06 | — | — |